Founded in 2018, InxMed is a clinical-stage oncology-focused biotech with the strategy of “Best-in-Disease Combination.” The company aims to find solutions for oncology drug resistance and tumor metastasis, especially resistance to PD-1.
Cancer; cancer screening; liquid biopsy
Nanjing InxMed Biotech (Chinese:南京应世生物), a global innovative drug R&D company, announced the completion of a USD 15 million Series B+ round of financing, exclusively backed by Hyfinity Fund.
The funds raised from this round will be used to advance the IN10018 pipeline clinical trials in China and the US simultaneously. The IN10018 targets multiple cancer types and uses different combination regimens. One phase II/III confirmatory clinical trial is to be launched in the second half of this year, targeting the approval of platinum-resistant ovarian cancer indicatio
IN10018 is a highly selective inhibitor of focal adhesion kinase (FAK). The pipeline is developed for multiple solid tumor indications which lack effective therapies. The indications include platinum-resistant ovarian cancer, NRAS-mutant melanoma, triple-negative breast cancer, head and neck cancers, and pancreatic cancer.
IN10018 has been granted Fast Track certification by FDA in August 2021 and obtained approval of breakthrough therapy designation by the China National Medical Products Administration (NMPA) in April 2022. The company is expected to disclose pre-clinical data at the ASCO meeting in June this year.
According to its official website, InxMed Biotech exclusively develops and operates IN10018 globally. The company's Nanjing Translational Medicine Center has conducted original exploratory studies on IN10018 and FAK targets. IN10018 is expected to overcome the barrier of tumor-stromal fibrosis to improve local immune function and become a new choice for combination therapy.
"With the development of a large number of internal independent research in the Nanjing R&D and Translational Medicine Center, our understanding of the drug resistance mechanism and microenvironmental fibrosis of solid tumors is deepening,” Dr. Wang Zaiqi, founder and chief executive officer of InxMed Biotech added, “We have developed the pipeline with different targets, mechanisms and drug combinations for multiple tumor types. It is rapidly advancing in China and the US.”